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ABSTRACT 
Background. P53, a crucial suppressor of tumor formation, generates multiple isoforms, whose 
role in disease is still being defined.  
Methods. By immunohistochemistry, we studied the expression of P53 protein and relative 
isoforms in benign papillomas (PA, n=9), inverted papilloma (IPA, n=10) and  squamous cell 
carcinomas (SCC, n=21).     
Results. In all lesions, P53 isoforms were significantly more expressed than P53. 
Immunoexpression of P53 matched with P53 isoforms in IPA as well as in SCC. Simultaneous 
immune-expression of P53 and related isoforms was double in SCC compared to IPA (10% vs 
24%), while expression of P53 isoforms was strongly reduced (70% vs 43%). IPA showed the 
highest percentage of both reactive cases and immunostained cells expressing P53 isoforms.  
Conclusions. We found the higher expression of P53 isoforms in IPA and SCC compared to PA, 
suggesting their role in local aggressiveness and malignant proliferation in head-neck lesions.  
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INTRODUCTION 
Tumor Protein (TP) 53  is a transcription factor controlling cellular proliferation and apoptosis by 
regulation of genes involved in cell-cycle arrest, DNA repair, and apoptosis (Moll et al., 2005; 
Vousden and  Lane, 2007). By alternative initiation of translation and splicing mechanisms, TP53 
may generate twelve varieties of transcripts such as FLP53, P53β, P53γ, Δ40α, Δ40β, Δ40γ, Δ133α, 
Δ133β, Δ133γ, Δ160α, Δ160β and Δ160γ. (Bourdon et al., 2005, Braithwaite and Prives, 2006; 
Lane and Levine, 2010, Sourget et al., 2014). Alternative initiation of P53 transcription involves an 
internal promoter, namely P2, located in exon 4, while the splicing processes of P53 occur in intron 
9 (Tuks and Crawford, 1989; Khoury and Borudon, 2010; Marcel et al., 2010; Marcel et al., 2012.).  
Canonical full length P53 (FLP3) protein is made of 393 amino acids (aa) building five major 
functional domains. These can be distinguished in amino terminal domain, showing two 
transactivation domains (TAD1 aa 1–40 and TAD2 aa 41–62), a proline-rich site (PXXP aa 63–94), 
a DNA-binding domain (DBD aa 95-290), a nuclear localization signal domain (NLS aa 291–325) 
and a carboxy-terminal oligomerization domain including oligomerization (OD aa 326–357) and 
negative-regulation sites (Neg aa 360–393) (Flaman et al., 1996; Levine et al., 2011). Therefore, the 
full set of P53 isoforms contains aa 160 through 325, retains NLS integrally, and DBD partially, 
and finally, may pass from cytoplasm to the nucleus binding specific DNA sequences (Courtois et 
al., 2002). Depending on tissue type, P53 isoforms act through the modulation of p53 
transcriptional activity and by triggering target genes involved in cellular proliferation and 
apoptosis (Aoubala et al., 2011; Khoury and Bourdon, 2011). 
Expressions of P53 isoforms have been reported in different malignant cancerous lesions such as 
breast cancer, ovarian, renal and colon carcinomas, suggesting a role of P53 isoforms in malignant 
proliferation (Bourdon et al., 2005; Marabese et al., 2008; Song et al., 2009; Fujita et al., 2009). 
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However, the role of P53 isoforms has not yet been clarified since even inflammatory lesions such 
as gastritis associated with Helicobacter pylori infection and benign colon adenoma may express 
spliced α forms (Fujita et al., 2009; Wei et al., 2012). More recently, we have reported on different 
patterns of immunohistochemical expression of P53 isoforms also in benign thyroid lesions, 
suggesting for the first time their role in the development of such lesions (Trovato et al., 2016). 
In the western world, squamous cell carcinoma of the head-neck region (SCCHN) has an incidence 
of nearly 5% (Jemal et al., 2007). Various studies proposed that a multi-step process, with 
accumulation of multiple genetic and epigenetic alterations, precedsthe appearance of SCCHN 
(Mao et al., 2004). Genetic alterations occurring in pre-malignant lesions have been correlated with 
the development of locally aggressive phenotype (Wittekindt et al., 2012). In the context of 
multistep carcinogenesis of SCCHN, inverted papilloma (IPA) has a central role since it is a benign 
lesion in nature, but often displays an aggressive behavior in terms of local invasiveness, 
recurrence, and malignant transformation (Lawson et al., 2003). IPA lesions account for 
approximately 0.5% to 4% of all primary nasal tumors, and occur prominently in males (3:1), 
mainly in Caucasian populations (Sauter et al., 2007). From 2 to 27% of IPAs have been reported to 
be associated with malignant changes (Barnes, 2002; Von Buchwald, 2007).  
Mutations of TP53 gene have been demonstrated by a frequency of 60–80%, and genetic alterations 
located in P53 core region, controlling DNA-binding, have been proposed as candidate markers of 
prognostic significance in SCCHN (Poeta et al., 2007). To date, expressions of p53, p53β, p53γ, 
Δ133p53, Δ133p53β and Δ133p53γ have been reported in SCCHN, but IPA and benign papilloma 
(PA) have not been evaluated  yet (Boldrup et al., 2007). Canonical P53 has been evaluated in IPA 
and SCCHN, but no data were available on P53 isoforms (Oncel et al., 2011). 
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The aim of our study was to investigate the expression of P53 paired with P53 isoforms in PA, IPA 
and SCCHN to determine what role P53 and related isoforms may have in these malignancies and 
in multistep carcinogenesis of the head-neck region. 
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MATERIALS AND METHODS 
Patients and Tissue Collection 
For this study, 40 unrelated patients were recruited, 37 men and 3 women (mean age ± SD: 68 ± 
18), of which 9 were affected by benign lesions and 31 by malignant proliferations of the head-neck 
region. Each patient was seen at the Unit of Odontostomatology of the University of Messina, 
where they received careful medical evaluation, including recording of past medical history and 
physical examination. Clinical diagnosis was supported by computed tomography analysis, and the 
benign lesions were catalogued as benign papillomas (PA, n=9), while the malignant lesions were 
HPV-unrelated tumors and were grouped into 10 inverted papillomas (IPA) and 21 carcinomas 
(SSCHN). None of the patients had received chemotherapeutic drugs before surgery.  
Methods and immunohistochemical evaluation 
Each surgical specimen was evaluated at the Unit of Integrated Ultrastructural Pathology, 
Department of Human Pathology, University of Messina. Specimens were fixed in 4% neutral 
buffered formalin and embedded in paraffin. Each block was cut into serial sections of 5-mm thick 
to carry out histochemical staining, such as hematoxylin and eosin (H&E), Periodic acid Schiff 
(PAS), and immunohistochemistry (IHC). According to the World Health Organization (WHO) 
standard criteria for tumor classification, the 21 carcinomas were catalogued as squamous cell 
carcinomas (SCCHN), and graded as well-differentiated (n=2), moderately differentiated (n =10) 
and poorly differentiated (n=9) (Barnes, 2002). In each section used for immunohistochemical 
procedures apparently normal peritumoral tissue was also included. 
IHC was carried out on  5-µm thick sections of selected blocks including either lesion or peri-lesion 
normal tissue. Two distinct monoclonal mouse antibodies were used to detect P53 and its isoforms. 
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The former recognizes an epitope located in P53 TAD1 region, between  amino acids 20–25, and 
reacts with FLp53, P53β and γ (DO-7, 1:100; DAKO, Carpinteria, CA, USA); the latter antibody 
recognizes an epitope located within the P53 DBD region, between amino acids 181–190, and binds 
the full set of P53 isoforms (DO-11, 1:500; Novus Biologicals Europe, Cambridge, UK; 
www.novusbio.com/NB100-65557). 
The antigen retrieval technique as described by Gown et al. (Gown et al., 1993) was used. The 
sections were deparaffinized with xylene and rehydrated through graded alcohol. Endogenous biotin 
was inactivated by addition of 0.05% (v/v) solution of streptavidin in phosphate-buffered saline 
(PBS) and endogenous peroxidase activity was suppressed by adding 0.3% (v/v) solution of 3% 
(v/v) H2O2 in absolute methanol. Slides, placed in 10 mM citrate buffer (pH 6.0), were heated for 
15 min in a microwave oven (Whirlpool AVM 300, power set at 500 watts) for three equal time 
periods. IHC procedures were performed by using an automated slide processing system designed 
by Autostainer Link 48 system (Dako). IHH staining was visualized by the LSAB system 
(Universal Dako LSAB® + Kit, Peroxidase, Carpinteria, CA, USA) whereas the colour reaction 
was developed by 3,3’-diaminobenzidine (DAB, Sigma) activated with 0.05% hydrogen peroxide.  
Sections were counterstained with Mayer’s haematoxylin, dehydrated and mounted. Specificity of 
the binding was assessed on appropriate negative controls, either by omitting the primary antiserum 
or by replacing the primary antiserum with normal mouse serum. In each of these conditions, no 
staining was evident. An immunoabsorption test was performed to confirm the specific 
immunoreactivity of each MAb. Specimens of breast carcinoma were used as appropriate positive 
controls for P53 antibodies.  
P53 and P53 isoforms immunoreactions were estimated using the following criteria: (i) number of 
positive cases; (ii) number of reactive epithelial cells per case: the count of reactive cells was based 
on evaluation of 1000 cells/case, using 40 X magnification; (iii) sub-cellular location of the 
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staining: cytoplasm and nucleus; (iv) semiquantitative grading of staining using a “Quickscore” 
method as proposed by Detre et al. (Detre et al., 1993). This method was based either on the 
proportions of immunostained cells or on the intensity of labelling. The immunostained cells were 
scored on a system from I to IV (I = 0-4% of cells; II = 5-19%; III = 20-39%; IV = 40-59%).  The 
intensity of immunostaining was graded from 0 to 3, corresponding with absence of labelling, weak, 
intermediate, and strong immunostaining, respectively. Grade I of immunoreactions was considered 
as unreactive; grade II of stained cells plus grade 2 or 3 of stain was indicated as class A; grade III 
plus grade 2 or 3 was recorded as class B; grade IV plus grade 2 or 3 was indicated as class C. 
Histological and immunohistochemical evaluations were carried out blindly by three different 
pathologists (M.T., M.S. and V.C.) with an inter-observer concordance of nearly 100%. Minimal 
inter-observer discrepancies were overcome by mean value.  
 
Statistical Analysis 
Data were evaluated for normal distribution and variance (mean ± standard deviation) and analyzed 
by the two-tailed Student’s t-test and χ2 test with Yates’ correction for continuity. Level of 
statistical significance was set at P < 0.05.  
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RESULTS 
Histological evaluation 
Microscopic diagnostic signs in PA cases included columnar and squamous epithelium cells, 
microcysts, mucinous cells associated with rare neutrophils, and microabscesses with reactive 
epithelial changes and oncocytic cells. 
Histological features of IPA were compatible with a benign proliferation composed of well 
differentiated columnar and ciliated respiratory epithelium focally showing squamous 
differentiation, along with invagination of the epithelium into underlying stroma. Necrosis was 
usually absent. 
Common microscopic appearance of SCCHN was seen in the areas of keratinizing, infiltrative nests 
of tumoral cells and surrounding peritumoral stromal desmoplasia. Squamous maturation was 
recognized by features of keratinization. Malignant cells were polygonal with distinct cell borders 
and abundant, eosinophilic cytoplasm. Necrosis foci were frequent. IPA signs were not detected. 
Immunohistochemistry 
Immunohistochemistry results are summarized in Table 1 and illustrated in Figures 1 and 2. All 
reactive samples showed immunostaining for FLP53 and the full set of P53 isoforms in both the 
cytoplasmatic and the nuclear compartments. P53 isoforms were more frequently immune-
expressed than the canonical P53 both in benign and malignant lesions (5/9 vs 0/9 and 16/31 vs 
6/31; P<0.05) (Table 1). With the exceptions of PA and well differentiated SCCHN, which did not 
show P53 immunostaining, canonical P53 expression matched P53 isoform immunoreactions.  
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Simultaneous immunoexpression of P53 and related isoforms was more than double in SCCHN 
compared to IPA (10% vs 24%; P=0.66), even if such differences didn’t reach statistical 
significance, probably due to the small numbers; in sharp contrast, expression of the P53 isoforms 
was greatly reduced (P= 0.022). (Table 1).   
Immunoreactivity of P53 isoforms was quite similar in benign and malignant lesions, appearing in 
approximately half of cases. However, when evaluating the cellular distribution of immunostaining, 
a different pattern of P53 isoform immunoreactions emerged. Only malignant lesions showed class 
C immunostaining and had the highest proportion of immunoreactive cells for P53 isoforms.  
P53 isoforms were more highly expressed in IPA lesions compared to PA (70% vs 55%) and 
SCCHN (70% vs 43%) (Table2). Furthermore, the IPA lesions showed the widest proportion of 
immunostained epithelial cells. While no lesion fell into the A category, all the IPA lesions 
belonged to both class B and C.  Peritumoral normal tissue was unstained at all.  
From SCCHN grading, it emerged that P53 isoforms were mainly expressed in moderate and poorly 
differentiated variants, which also showed the highest proportion of immunostained squamous 
carcinomatous cells. Furthermore, in reactive SCCHN, grade A immunostaining for P53 isoforms 
was observed in the adjacent peritumoral normal tissue.   
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DISCUSSION 
In the present study, we evaluated the expression of P53 and its isoforms in a series of head-neck 
lesions encompassing the whole spectrum of epithelial squamous proliferation, from benign lesions 
(PA) along with local aggressive malignancy (IPA) to true malignancy (SCCHN).  
In our study we first evaluated the expression of P53 and its isoforms in three types of head-neck 
lesions, ranging from benign papillomas to malignant SSCHN passing through IPA, in comparison 
with the peri-tumoral normal tissue, in order to identify differences in P53 and isoforms expression 
between such lesions. We firstly demonstrated that P53 isoforms are expressed in all the steps of 
squamous carcinogenesis, even in the early stages, by a percentage of cases close to 50%, while P53 
expression seems to be associated with local aggressiveness appearance and true malignancy.  
Secondly, our study documented a distribution of P53 isoforms significantly different in IPA 
compared to PA and SCCHN. In fact, IPA showed the highest percentage of reactive cases and the 
largest number of immunoreactive epithelial cells, suggesting a role of P53 isoforms in the 
development of local aggressiveness. Indeed, such a role may be hypothesized, since the Δ133 
isoforms of P53 have been reported as fundamental to stimulate migration and tubulogenesis 
processes in tumour cells (Bernard et al., 2013). Taken all of the above, P53 isoforms might act in 
IPA lesions by driving local invasion of epithelial cells.  
The third interesting point of our results was the demonstration that simultaneous immunoreactions 
of P53 and its isoforms were increased in SCCHN compared to IPA, while, conversely, expression 
of the P53 isoforms was reduced in SCCHN.  In fact, we found that 60% of IPA displayed the 
expression of P53 isoforms only, compared to 19% of SCCHN. 
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To date, very few reports have investigated the role of P53 isoforms in head-neck lesions, although 
it is currently accepted that disruption of the P53 pathway is one of the most common genetic 
alteration in head-neck cancers. Mutations of P53 have been reported in up to 80% of SSC (Poeta et 
al., 2007), and canonical p53 over-expression was been found to be associated with malignant 
potential in pre-malignant head-neck lesions (Oncel et al., 2011; Gujrathi et al., 2003). Gujrathi et 
al. found that four of the five cases of malignancy associated with IPA overexpressed p53, while 
none of the benign cases of IPA demonstrated such an over-expression. More recently, Oncel S. et 
al. studied the expression of the cell cycle regulators P53, P62, P21 and P27 in IPA and SCC, 
revealing elevated levels of P53 expression in SCC compared to IPA. On this basis, it has been 
suggested that overexpression of p53 may serve as a marker of malignant transformation of IPA, to 
screen out papilloma lesions with a potential for dysplasia or carcinoma.  However, only the 
canonical P53 expression was tested, and benign PA lesions, as well as the peritumoral normal 
tissue, were not evaluated in this study.  
Prior to us, Boldrup and co-workers first reported the expression of canonical P53 and numerous 
P53 isoforms, P53β, P53γ, Δ133 P53, Δ133 P53β and Δ133 P53γ, both in SCCHN lesions and in 
paired normal tissues (Boldrup et al., 2007). In this study, SCC lesions were studied paired with 
normal tissues, but benign papillomas, as well as IPA, were not evaluated. Our report on the 
distribution of P53 isoforms in different steps of squamous carcinogenesis may add novel findings 
to the debate on the relationship between such lesions and molecular pathways regulating cell cycle 
and apoptosis. Taken together, our data suggest that analysis of P53 along with isoforms expression 
may be a suitable candidate marker to explore squamous cell proliferation referring to invasive 
malignancy.  
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LEGEND FOR FIGURES 
Figure 1. Immunoreactions for P53 isoforms in papilloma, inverted papilloma, squamous cell 
carcinoma and peritumoral normal tissue of squamous cell carcinoma. 
Panel A and D: class B immunoreactivity in a papilloma and normal tissue surrounding squamous 
cell carcinoma, respectively; that is, 20-39% of stained cells plus intermediate or strong 
immunostaining as specified under Material and Methods (original magnification X200). 
Panels B and C: class C immunostaining in an inverted papilloma and poorly differentiated 
squamous cell carcinoma, respectively; that is, 40-59% of stained cells plus intermediate or strong 
immunostaining (original magnification x400). 
Figure 2. Immunoreactions for P53 in cases of papilloma, inverted papilloma, squamous cell 
carcinoma and paired peritumoral normal tissue. 
Panel A and D: unstained P53 papilloma and normal tissue surrounding poorly differentiated 
squamous cell carcinoma, respectively (original magnification x200).  
Panels B: class A immunostaining in an inverted papilloma; that is 5-19% of stained cells plus 
intermediate or strong immunostaining (original magnification x400). 
Panel C: class B immunoreaction in moderate differentiated squamous cell carcinoma (original 
magnification x400). 
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Table 1. Immunoreactivity for P53 and its isoforms in our series of 40 patients affected by either 
benign or malignant lesions of head and neck. 
 
The immunoreactivities for Δ133 isoforms of P53 were classified as Class A, B, C and D by using the 
“Quickscore” method, as reported in Material and Methods. 
 
	 	
Number	
of	cases	
P53		 P53	isoforms		
Lesions	 Immunoreactive	
cases	(%)	
Cellular	distribution	of	
immunoreactions	(%)	
Immunoreactive	
cases	(%)	
Cellular	distribution	of	
immunoreactions	(%)	
	 	 Reactive	 A*	 B**	 C***	 Reactive	 A*	 B**	 C***	
Benign	 9	 0	 0	 0	 0	 	5	(55%)	 40	 60	 0	
Malignant		
(Inverted	papilloma	and	
Squamous	carcinoma)	
31	 6	(19%)	 50	 50	 0	 	16	(52%)		 12	 38	 50	
	 	 	 	 	 	 	 	 	 	
Pathological	lesions	 	 	 	 	 	 	 	 	 	
Papilloma	 9	 0	 0	 0	 0	 5(55%)	 40	 60	 0	
Inverted	papilloma	 10	 1	(10%)	 100	 0	 0	 7	(70%)	 0	 29	 71	
Squamous	carcinoma	 21	 	5	(24%)	 40	 60	 0	 9	(43%)	 22	 12	 66	
	 	 	 	 	 	 	 	 	 	
Squamous	carcinoma	
Histological		grading	
	 	 	 	 	 	 	 	 	
Well	differentiated	 2	 0	 0	 0	 0	 0	 0	 0	 0	
Moderately	
differentiated		
	
10	
	
	2	(20%)	
	
100	
	
0	
	
0	
	
	5	(50%)	
	
40	
	
0	
	
60	
Poorly	differentiated	
	
9	 3	(33%)	 0	 100	 0	 49	(44%)	 0	 25	 75	
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